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A b s t r a c t
Background and aim: Recent meta-analyses indicate that the pooled prevalence of resistant hypertension (RHT) barely differs 
between the sexes. However, differences between women and men with RHT in patient characteristics, associated factors, 
and hypertension (HT) management are still not well-described.
Methods: In the cross-sectional questionnaire-based observational study we included 7306 hypertensive females and 
5069 hypertensive males, ≥ 18 years old, and treated for at least 12 months with antihypertensive drugs. We defined HT 
control as blood pressure (BP) levels both < 140 mm Hg/< 90 mm Hg. Patients were divided into three groups: controlled 
HT, uncontrolled HT (not fulfilling the criteria of RHT), and RHT (uncontrolled HT despite using three antihypertensive drugs 
including diuretic). Cardiovascular (CV) risk was evaluated according to 2013 ESH/ESC guidelines.
Results: There were no differences in the rates of controlled HT (47.6% vs. 47.0%), uncontrolled HT (27.3% vs. 28.8%), and 
RHT (25.1% vs. 24.2%) between women and men, respectively (p = 0.17). Among patients with RHT, women were older than 
men and had lower diastolic BP and estimated glomerular filtration rate (eGFR) as well as higher pulse pressure (PP). Cerebro-
vascular diseases (16.9% vs. 14.3%; p = 0.062), abdominal obesity, and metabolic syndrome (MS, 70.5% vs. 60.1%; p < 0.001) 
were more frequent among women than men with RHT. Women with RHT had higher rate of high/very high added CV risk 
in comparison to men. In a multivariate model higher PP, presence of MS, CV disease, and eGFR < 60 mL/min/1.73 m2 were 
related to the presence of RHT both in males and females. In women RHT was also related to abdominal obesity, cerebro-
vascular diseases, and diseases causing disability. In men, RHT was additionally related to diseases requiring treatment with 
non-steroidal anti-inflammatory drugs.
Conclusions: Although there were no differences in the rate of RHT between women and men, we identified gender-related 
differences in CV risk profiles in RHT patients and in factors related with the presence of RHT. When divided into age groups, 
RHT was less frequent in women aged less than 40 years and aged between 40 and 65 years, and among patients 65 years 
and older there was a tendency towards a higher rate of HT in women.
Key words: antihypertensive treatment, cardiovascular risk, resistant hypertension
Kardiol Pol 2017; 75, 5: 421–431
www.kardiologiapolska.pl
Katarzyna M. Hanus et al.
422
INTRODUCTION
Hypertension (HT) is more common in women than in men 
in ageing populations. In Europe and the United States, one in 
three adults presents with arterial hypertension. Noteworthy 
are the differences between women and men in younger 
age groups (18 and 29 years), showing a prevalence of 1.3% 
in women and 8.5% in men and 7.3% in women vs. 15.8% 
in men in people at the age of 30–44 years. No major sex 
differences in clinical manifestations of HT outside of preg-
nancy-related HT have been described [1–5].
According to current clinical practice guidelines, no differ-
ences between men and women have been documented re-
garding diagnostic approaches for HT. As far as the differences 
between genders in hypertensive patients are concerned, 
female sex stands among the factors associated with a higher 
prevalence of white coat HT, whereas male sex is related to 
increased prevalence of masked HT [1–5].
Hypertensive women sustain higher left ventricular ejec-
tion fraction but they exhibit less regression under medical 
therapy and they have estimated three-fold higher risk for 
developing congestive heart failure (HF) or stroke compared 
with men. Women with HT develop more vascular and myo-
cardial stiffness than men at old age, and more often have 
isolated systolic HT, reflecting aortic stiffness [1–5].
It has been shown that patients with resistant hyperten-
sion (RHT) are at disproportionately higher risk for target organ 
damage and cardiovascular (CV) events, compared with the 
general hypertensive population. The recognition and iden-
tification of individuals with RHT is of particular importance, 
given the fact that they may require further diagnostic evalua-
tion for specific interventions. Recent meta-analyses indicate 
that the pooled prevalence of RHT barely differed between 
sex. However, differences between male and female RHT 
patients in their characteristics, associated factors, and HT 
management are not well-characterised [6].
The aim of the analysis of the Pol-Fokus study was to com-
pare women and men with RHT and to analyse if in patients 
with RHT there are sex differences in associated factors and 
HT treatment methods.
METHODS
The methodology of the Pol-Fokus study has already been 
published [7]. In brief, Pol-Fokus was a large, observational, 
cross-sectional survey of hypertensive subjects managed by 
general practitioners (GPs), cardiologists, and hypertension 
specialists throughout the Polish territory. The study was ap-
proved by the Ethics Committee of Jagiellonian University in 
Krakow, Poland and all participants provided informed con-
sent. Nine hundred and seventy-eight GPs and 286 specialists 
(cardiology and hypertensiology) from all provinces in Poland 
participated in the Pol-Fokus study [1, 7]. 
The methods of selection of this group have already been 
described in detail [1, 7, 8].
The Pol-Fokus study included hypertensive patients 
meeting the following criteria: age 18 years or more, HT 
treated for at least one year, with at least one visit to the doc-
tor (participating in the study) over the last year. They had to 
be free from any acute disease in the preceding four weeks 
and from known secondary causes of HT. After exclusion of 
data obtained from doctors who did not achieve the specific 
quota or who provided incomplete questionnaires, as well as 
patients who were included despite not meeting the inclusion 
criteria and patients with no data regarding antihypertensive 
treatment, we finally analysed data from 12,375 patients. 
Patients underwent standard clinical evaluation. The 
known duration of the HT was recorded. Weight and height 
as well as waist circumference were measured. Body mass 
index (BMI) was calculated. Abdominal obesity was defined 
as a waist circumference > 102 cm in men and > 88 cm 
in women. Currently used antihypertensive medications 
were also documented. Plasma sodium, potassium, glucose, 
creatinine, total cholesterol, low-density lipoprotein (LDL) 
cholesterol, high-density lipoprotein (HDL) cholesterol, and 
triglycerides concentration were measured, history of coronary 
artery disease (CAD), previous myocardial infarction, HF, ar-
rhythmias, cerebrovascular diseases (CVD, including previous 
transient ischaemic attack, or stroke), asthma or chronic ob-
structive pulmonary disease, depression or anxiety, diabetes, 
and other diseases were assessed. The estimated glomerular 
filtration rate (eGFR) was calculated according to the Modifica-
tion of Diet in Renal Disease (MDRD) study formula. CV risk 
(stratification into two groups: low/moderate and high/very 
high added risk) and characteristics of metabolic syndrome 
(MS) were evaluated according to the 2013 European Society 
of Hypertension/European Society of Cardiology (ESH/ESC) 
guidelines [2].
Blood pressure (BP) was measured in patients in the sitting 
position after a 5 min rest. Based on upper arm circumfer-
ence, an appropriately sized cuff was put 2 cm above the 
antecubital fossa. Three consecutive readings were performed. 
The average of these three readings was recorded. Each 
participating doctor was provided with a detailed instruction 
for BP measurement. Use of devices with proven accuracy 
was recommended. 
We defined HT control as BP levels lower than 140 mm Hg 
for systolic BP (SBP) and lower than 90 mmHg for diastolic BP 
(DBP). Hypertension was defined as resistant when a therapeu-
tic strategy including diuretic and two other antihypertensive 
drugs failed to lower SBP and DBP values to < 140 mm Hg 
and < 90 mm Hg. For this analysis, we divided patients into 
three groups: with controlled HT, uncontrolled HT (not fulfill-
ing the criteria of RHT), and RHT. 
Statistical analysis
Data analysis was carried out using the statistical software 
PASW Statistics 18 (SPSS Inc., Chicago, Illinois, United States). 
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The results are presented as mean ± one standard deviation 
or median and interquartile range. The values of variables 
were compared between groups: in the case of continuous 
and discrete variables by Student’s t test, Mann-Whitney test, 
or univariate ANOVA analysis with Duncan post-hoc test, and 
in the case of categorical variables by c2 test or Fisher exact 
test. Multivariate logistic regression models were performed 
to determine the combined effect of several variables on the 
prevalence of specific characteristics. For multivariate analy-
sis, the variables with significant association were included. 
Multicollinearity was checked by variation inflation factor. 
P < 0.05 was considered statistically significant.
RESULTS
We included 7306 women (mean age 65.6 ± 11.8 years, range 
18–98 years) and 5069 men (mean age 61.7 ± 12.6 years, 
range 18–98 years). Among the women 3476 (47.6%) 
had controlled HT, 1997 (27.3%) — uncontrolled HT, 
and 1833 (25.1%) — RHT; whereas among men it was 
2381 (47.0%), 1461 (28.8%), and 1227 (24.2%), respectively 
(p = 0.17; Fig. 1). The mean age of patients with RHT was 
significantly higher in women than in men (Table 1). 
In patients with RHT, there were no differences between 
males and females in SBP levels. Women with RHT were 
characterised by lower DBP and higher pulse pressure (PP) 
than men.
Among patients with RHT women more often had MS 
and abdominal obesity than men. There was no difference in 
the frequency of diabetes between men and women (Table 2). 
Lower levels of eGFR were observed in women, and the 
prevalence of eGFR < 60 mL/min/1.73 m2 was significantly 
higher in women in comparison with men (Tables 1, 2). There 
were no differences between women and men in sodium, 
potassium, total cholesterol, LDL-cholesterol, HDL-cholesterol, 
triglycerides, and glucose levels (Table 1). Women with RHT 
had higher rate of high/very high added CV risk in comparison 
to men (Fig. 2). 
There were no differences in the rates of CV diseases and 
CAD between men and women with RHT. The prevalence of 
HF was higher in men than in women. Other diseases includ-
ing depression, diseases requiring the use of non-steroidal 
anti-inflammatory drugs, and diseases causing disability were 
more frequent in women with RHT than in men (Table 2). 
There was no difference between women and men in 
the number of antihypertensive drugs. There were also no 
differences in the rate of use of particular antihypertensive 
drug classes between men and women with RHT, except for 
alpha-blockers, which were used more often by men (Table 3). 
We analysed the rate of use of the preferred three-drug 
combination (angiotensin converting enzyme inhibitor [ACEI] 
or angiotensin II receptor blocker [ARB] and calcium chan-
nel blocker [CCB] and thiazide/thiazide-type diuretic), and 
there was no difference between men and women in either 
the whole group of patients or in any particular clinical situ-
ation (Fig. 3).
To assess which factors are independently related to RHT 
in men and women, we performed a multivariate analysis 
including sex, age, PP, abdominal obesity, MS, diabetes, 
CAD, CVD, diseases requiring treatment with non-steroidal 
anti-inflammatory drugs, diseases causing disability, depression 
Figure 1. Prevalence of controlled, uncontrolled, and resistant hypertension (HT) in men and women according to the age groups; 
M — men; W — women
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Figure 2. Comparison of cardiovascular risk stratification in 
participating women and men according to the 2013 Euro-
pean Society of Hypertension/European Society of Cardiology 
clinical practice guidelines
or anxiety, and eGFR of less than 60 mL/min/1.73 m2. Fac-
tors independently related to the RHT both in men and 
women were higher PP, MS, CAD, and an eGFR of less than 
60 mL/min/1.73 m2. Additionally, in women the presence of 
RHT was independently associated with abdominal obesity, 
prior CVD, and diseases causing disability, whereas in men the 
presence of RHT was independently associated with the use 
of non-steroidal anti-inflammatory drugs (Table 4). 
DISCUSSION 
There is growing body of evidence in current literature about 
patients’ characteristics, related risk factors, and therapy 
regarding RHT. Nevertheless, little is known about gender 
differences in patients with RHT.
In most studies male sex seems to be a risk factor of RHT 
[3, 9–11]. The Anglo Scandinavian Cardiac Outcome Trial 
(ASCOT) conducted on previously untreated patients revealed 
that baseline SBP and choice of subsequent antihypertensive 
therapy were the two most important determinants of RHT [3]. 
However, other factors including male sex and increased BMI 
were also significant determinants of RHT in this population. 
The opposite point of view is presented in the study of 
Smith et al. [12], indicating that, among other factors, female 
sex, increasing age, and BMI were associated with RHT. It 
should be noted that results of Pol-Fokus do not provide strong 
evidence that female or male gender may be a significant risk 
factor of RHT.
In other studies, the prevalence of RHT between females 
and males varied depending on the analysed population. 
The study by Egan et al. [9] performed between 2007 and 
2010 in 468,877 hypertensive patients showed that age, the 
percentage of men, BMI, and the frequency of other factors 
were higher in those with apparent RHT as compared to other 
groups of hypertensive patients. 
Achelrod et al. [13], in a systematic review and me-
ta-analysis based on nine observational studies including the 
Northern American population, indicated that differences 
in RHT prevalence between sexes are negligible, whereas 
in a cross sectional study on 1217 Malaysian, Chinese, and 
Indian patients with hypertension, 8.8% of the participants 
had RHT and 64.4% of them were females [14]. 
However, it should be noted that other available studies 
support the concept that female sex is more frequent in RHT 
patients [5, 15, 16].
Our study showed that the prevalence of RHT in patients 
with HT was 24.7%, which is relatively high. There was no 
difference in the frequency of RHT between women and men 
(Fig. 1); however, the analysis of age subgroups revealed that 
RHT was less frequent in women at the age of < 40 years and 
40–65 years. Among patients 65 years old and above there 
was a tendency towards higher rate of HT in women (Fig. 1). 
This observation may be because women in the 
Pol-Fokus study were generally older than men, which 
— based on the scientific data — confirms the relationship 
between higher age and more frequent prevalence of RHT 
[9, 14, 17]. 
Based on the NATPOL PLUS study conducted in 2002, 
the prevalence of HT in the general population also differs 
between age groups. The older the patient, the higher the 
observed frequency of HT. In 40–59-year-old people the 
prevalence of HT was 34% (female [F]: 34%, male [M]: 34%), 
and in older than 59 years it was 57% (F: 60%, M: 54%). 
Multivariate logistic regression revealed a significant impact of 
the older age, obesity, and educational level on the frequency 
of HT in the Polish population [4]. 
Contrary to the NATPOL PLUS study, our results indi-
cate that significant differences in the prevalence of RHT 
between females and males occurred in patients at the age 
of 45–60 years.
The prevalence of vascular risk factors including obesity, 
hyperlipidaemia, diabetes, CAD, or CV disease is higher in 
subjects with RHT, as compared to patients with controlled 
HT [7, 8]. However, in our study it was shown that there 
were no significant differences in the occurrence of risk fac-
tors between the genders except for MS and renal function 
decrease manifested by eGFR less than 60 mL/min/1.73 m2. 
The observed lower eGFR in women with RHT may result 
from their higher age at the time of RHT diagnosis and from 
the use of the MDRD study formula to calculate eGFR. Using 
this formula results in lower eGFR values in women than in 
men. Additionally, the higher prevalence of renal dysfunction 
in patients with RHT compared to those without RHT may be 
due to higher PP values. PP was higher in women with RHT 
in comparison with men with RHT, which is associated with 
a detrimental effect on renal vasculature.
It is highlighted in the current guidelines that patients 
with HT need to be classified not only regarding the severity 
of HT but also based on CV risk evaluation [1]. 
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Table 4. Multivariate model assessing an independent association of factors with the presence of resistant hypertension
Factors related with  
resistant hypertension
Male Female
OR 95% CI P OR 95% CI P 
Pulse pressurea 1.66 1.55–1.79 < 0.001 1.86 1.75–1.98 < 0.001
Abdominal obesity – – – 1.24 1.02–1.51 0.035
Metabolic syndrome 1.86 1.55–2.22 < 0.001 1.44 1.18–1.77 < 0.001
Diabetes – – – – – –
Coronary artery disease 1.41 1.18–1.67 < 0.001 1.80 1.55–2.10 < 0.001
Cerebrovascular disease – – – 1.25 1.01–1.55 0.039
Treatment with NSAIDs 1.48 1.20–1.82 < 0.001 – – –
Diseases causing disabilityb – – – 1.34 1.09–1.64 0.005
Depression/anxiety – – – – – –
eGFR < 60 mL/min/1.73 m2 1.37 1.06–1.77 0.015 1.23 1.06–1.43 0.008
aFor 10-mm Hg increase; bFor 10-year increase; CI — confidence interval; eGFR — estimated glomerular filtration rate; NSAIDs — nonsteroidal 
anti-inflammatory drugs; OR — odds ratio
Figure 3. The frequency of using the preferred three-drug combinations in relation to coexisting clinical conditions in patients 
with resistant hypertension, P value for comparison between patients with or without coexisting clinical condition; ACE — angio-
tensin converting enzyme; ARB — angiotensin receptor blocker; CCB — calcium channel blocker; eGFR — estimated glomerular 
filtration rate; TD — thiazide/thiazide-type diuretic; W — women; M — men; *p value for the patients with or without coexisting 
clinical condition
In our study, the assessment of the CV risk according to the 
2013 ESH/ESC guidelines showed that women with RHT more 
frequently had high and very high CV risk than men with RHT.
Comparing to the WOBASZ and WOBASZ-Senior 
study conducted in Polish population at the age of 20– 
–74 and < 75 years, our results are similar mostly due to the 
higher frequency of abdominal obesity in women in compari-
son with men [8, 18].
It was also shown in our study that depression and dis-
eases causing disability were more frequent in women than 
in men with RHT. 
Our results also indicate that, in general, there were no 
significant differences between the preferred drug combina-
tion schemes. Both ACEI and ARB were used in most of the 
patients with RHT equally in men and women, followed by 
thiazide/thiazide-type diuretics, beta-blockers, and CCB. 
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The evaluation of the preferred drug combination based 
on the 2013 ESH/ESC guidelines showed that a regimen 
consisting of ACEI or ARB, CCB, and thiazide/thiazide-type 
was used in less than half of the patients with RHT, but more 
often in those with coexisting MS or diabetes [2]. 
In our study, the rate of alpha-blockers intake was higher 
in men in comparison to women with RHT, which might be 
because alpha-blockers are more frequently prescribed in the 
male population with benign prostatic hyperplasia.
Although in the presented study there was only one sig-
nificant difference in the drug intake between the genders, 
it should be noticed that there are reports indicating some 
differences in pharmacokinetics, pharmacodynamics, and 
adverse drug reactions between men and women [19].
A major strength of our study is that we analysed RHT in 
a large cohort of patients in Poland characterised by clinical 
features and cluster of CV risk factors.
Limitations of the study
Our study has certain limitations. First, the adherence to an-
tihypertensive treatment could not be assessed or controlled. 
Our estimation was based on the physician’s judgement of 
the patient’s adherence to treatment. The lower rate of pa-
tients with LDL-cholesterol levels below the treatment goal 
among patients with RHT might suggest their nonadherence 
to a recommended treatment. Moreover, we based our 
analysis on clinical BP measurements, and BP monitoring 
was not used to exclude those with white coat HT. Another 
limitation, typical for observational studies, is the lack of 
forced titrated treatment. Therefore, among patients with un-
controlled HT treated with two or even three drugs (without 
diuretic), there is a potential subgroup of patients with RHT. 
Yet another limitation was the cross-sectional design of the 
study, which did not allow us to examine the effect of RHT 
on the development and progression of complications. The 
prevalence of RHT could have been overestimated in both 
men and women because the participants were not checked 
for secondary forms of HT; therefore, we cannot exclude 
the possibility that some patients with secondary HT were 
misclassified as having RHT.
Additionally, most of the participating patients underwent 
a laboratory examination, and a substantial percentage did 
not undergo a carotid ultrasound or microalbuminuria estima-
tion before the evaluation. The lack of this information about 
vascular and renal target organ damage may have led to an 
underestimation of CV risk in these patients.
CONCLUSIONS
In conclusion, our study based on a large group of treated 
hypertensive men and women showed that RHT is relatively 
common in both genders, with the frequency being com-
parable in both groups. However, with the exception of MS 
and renal function, no other major differences in clinical 
characteristics, associated factors, and HT treatment were 
found between both groups. 
Moreover, women with RHT in comparison to men are 
characterised more often by a high and very high CV risk and 
therefore should require appropriate intensive drug therapy 
interventions. The underuse of preferred antihypertensive 
drug combinations may contribute to uncontrolled BP levels 
both in women and men.
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Metody: Do przekrojowego badania, opartego na ocenie ankietowej, włączono 7306 kobiet i 5069 mężczyzn chorych na 
HT, zgłaszających się na rutynową wizytę u lekarza rodzinnego lub u lekarza specjalisty. Lekarze uczestniczący w badaniu 
zostali dobrani tak, aby zapewnić reprezentatywną grupę pacjentów z każdego województwa. Kryteria włączenia obejmowały 
wiek ≥ 18 lat i co najmniej roczny wywiad farmakologicznego leczenia HT. Pomiar ciśnienia tętniczego wykonano 2-krotnie 
w pozycji siedzącej zgodnie z zasadami przyjętymi w wytycznych European Society of Hypertension/European Society of 
Cardiology (ESH/ESC); obliczono średnią wartość z dwóch pomiarów. Prawidłowa kontrola HT została zdefiniowana jako 
wartości ciśnienia < 140 mm Hg i < 90 mm Hg. Pacjenci zostali podzieleni na trzy grupy: nadciśnienie tętnicze kontrolo-
wane, niekontrolowane (niespełniające kryteriów RHT) oraz oporne nadciśnienie tętnicze (niekontrolowane nadciśnienie 
mimo stosowania minimum 3 leków hipotensyjnych, w tym diuretyku). Ryzyko sercowo-naczyniowe zostało ocenione wg 
wytycznych ESH/ESC z 2013 roku.
Wyniki: Nie stwierdzono istotnych różnic w stopniu kontroli HT: kontrolowane (47,6% vs. 47,9%), niekontrolowane (27,3% 
vs. 28,8%) oraz oporne (25,1% vs. 24,4%) między kobietami i mężczyznami (p = 0,17). RHT występowało rzadziej u kobiet 
niż u mężczyzn poniżej 40. rż. (9,4% vs. 19,4%; p = 0,083) oraz pomiędzy 40. a 65. rż. (20,4% vs. 23,3%; p = 0,019), na-
tomiast wśród chorych powyżej 65 lat RHT częściej obserwowano u kobiet (28,1% vs. 26,4%; p = 0,089). U chorych z RHT 
nie stwierdzono różnic między kobietami i mężczyznami w wartościach skurczowego ciśnienia tętniczego. Kobiety z RHT 
charakteryzowały się niższymi wartościami rozkurczowego ciśnienia tętniczego i wyższymi wartościami ciśnienia tętna w po-
równaniu z mężczyznami. W grupie chorych z RHT kobiety, w porównaniu z mężczyznami, cechowały się starszym wiekiem 
i niższą wartością oszacowanego wskaźnika filtracji kłębuszkowej (eGFR). Przebyty udar/przejściowy atak niedokrwienny mózgu 
(TIA; 16,9% vs. 14,3%; p = 0,034), otyłość brzuszna i zespół metaboliczny (MS; 70,5% vs. 60,1%; p < 0,001) były częstsze 
wśród kobiet niż mężczyzn z RHT. Ryzyko sercowo-naczyniowe wysokie i bardzo wysokie było znacząco częstsze wśród 
kobiet z RHT w porównaniu z mężczyznami z RHT (70,9% vs. 67,3%; p < 0,001). Mężczyźni z RHT częściej otrzymywali 
antagonistów aldosteronu (16,1% vs. 13,8%) oraz alfa-adrenolityki (8,9% vs. 2,1%; p < 0,001), rzadziej zaś diuretyki tiazydo-
we/tiazydopodobne (78,5% vs. 81,3%; p = 0,032). W analizie wieloczynnikowej parametrami związanymi z obecnością RHT 
były, zarówno u kobiet, jak i u mężczyzn: wyższe ciśnienie tętna, MS, choroba wieńcowa i eGFR < 60 ml/min/1,73 m2. Wśród 
kobiet RHT było również dodatkowo istotnie związane z otyłością brzuszną, przebytym udarem/TIA oraz obecnością chorób 
związanych z niepełnosprawnością. Z kolei u mężczyzn RHT dodatkowo wiązało się z chorobami wymagającymi stosowania 
niesteroidowych leków przeciwzapalnych.
Wnioski: Pomimo braku różnic w częstości występowania RHT między kobietami i mężczyznami wyodrębniono różnice 
w odniesieniu do profilu czynników ryzyka sercowo-naczyniowego i stanów związanych z RHT.
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